Navigation Links
ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ending December 31, 2011
Date:4/2/2012

valents of approximately $215,000.

Revenues

Revenues for the fourth quarter of 2011 were $256,000, compared to $1,029,000 for the fourth quarter of 2010.  The decrease of approximately $773,000 in revenues from the fourth quarter of 2010 compared to the fourth quarter of 2011 was primarily due to decreased licensing fees as the prior year included the recognition of $751,000 in unamortized licensing fees.

For the year ending December 31, 2011, revenues were $485,000, compared to $1,557,000 for the same period of 2010.  The decrease of approximately $1,072,000 was due primarily to the following factors; a reduction of $988,000 in OraDisc™ related licensing fees and a decrease of $186,000 in Zindaclin® related licensing and royalty fees due to our divestiture of this product in September 2010, this was partially offset by increased product sales.

Research and Development

Research and development expenses for the fourth quarter of 2011 were $198,000, including $17,000 in share-based compensation, compared to $309,000, including $32,000 in share-based compensation, for the fourth quarter of 2010.  The decrease of approximately $111,000 in research and development expenses was primarily was due primarily to lower costs for direct research costs of $85,000.

For the year ending December 2011, research and development expenses were $950,000, including $70,000 in share-based compensation, compared to $1,260,000, including $136,000 in share-based compensation, for the same period in 2010. The decrease of approximately $311,000 in research and development expenses was due primarily to lower costs for regulatory fees of $140,000, direct research costs of $73,000, clinical testing costs for our wound care technologies of $46,000 and scientific compensation costs of $30,000.

Selling, general and administrative

Selling, general and administrative expenses for the fourth quarter o
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Announces Conference Call
8. ULURU Inc. Provides Altrazeal® Clinical Update
9. ULURU Inc. Reports Third Quarter 2010 Financial Results
10. ULURU Inc. to Raise $500,000 in Registered Direct Offering
11. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Mass. , Nov. 25, 2014 Reinforcing ... Royal Philips (NYSE: PHG AEX: ... and Drug Administration (FDA) for its IQon Spectral ... imaging. This first-of-its kind technology adds a new dimension ... offering the ability to characterize structures based on their ...
(Date:11/26/2014)... , Nov. 25, 2014  Array BioPharma ... announced that its Chief Executive Officer, ... following upcoming conferences.  The public is welcome ... on the Array BioPharma website:  www.arraybiopharma.com ... 2014Time:1:30 p.m.  Eastern Time Location: Palace Hotel, ...
(Date:11/26/2014)... Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Healthcare Conference in New York on ... . Dr. Helen Torley , President and Chief ... presentation will be webcast through the "Investors" section of Halozyme,s ... be made available for 90 days following the event. To ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... Feb. 23, 2012  BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX® in ... today announced that its partner Auxilium Pharmaceuticals, Inc. ... Pharmaceuticals Ltd. (Actelion) for the long-term development, supply ...
... Feb. 23, 2012 Idenix Pharmaceuticals, Inc. (NASDAQ: ... discovery and development of drugs for the treatment of ... the fourth quarter and year ended December 31, 2011 ... virus (HCV) development pipeline. Operational ...
Cached Medicine Technology:BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico 2BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico 3BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 7Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 8
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, Jennifer E. ... Award from The American Association of Nurse ... of nurse practitioners. The Distinguished Preceptorship Award recognizes ... a significant contribution toward increasing the awareness and ... Practitioners (AANP) is the largest full-service national professional ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Vultures have developed highly ... ingest when eating dead animals, researchers report. The ... on the faces and in the guts of 50 ... On average, the faces of the vultures had more ... in their guts, the study found. The findings ...
(Date:11/26/2014)... Exposure to peanut protein in household dust may increase ... skin condition eczema, a new study reveals. About ... are allergic to peanuts. And severe eczema in infants ... the researchers noted. The new study included 359 ... examined the amount of peanut protein the children were ...
(Date:11/26/2014)... 2014 (HealthDay News) -- Parents need to take an ... an expert warns. Parents must make sure sports-playing ... Dr. David Dodick, chair of the American Migraine Foundation ... College of Medicine in Scottsdale, Ariz. in an American ... Any coach involved with teens sports needs to ...
(Date:11/24/2014)... Los Angeles, CA (PRWEB) November 24, 2014 ... to bringing its readers reviews of affordable skin care ... , the casual blog offers readers a wide variety ... the market as well as organic skincare alternatives. , ... Healthy Skin Care Journal’s main content includes thoroughly researched ...
Breaking Medicine News(10 mins):Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Parents Need to Take Lead on Teen Concussion Prevention 2Health News:Skin Care Advice Blog The Healthy Skin Care Journal Now Accessible to the Public 2
... a bacteria resistant to certain antibiotics. This bacteria occurs ... especially in hospitals and nursing homes and is known ... the Netherlands, Sweden, and Norway, where MRSA has been ... facing an increase in incidence with the rates starting ...
... – 'In Zambia, people in the tourist resort city of ... dead chickens at the owners backyards'. // ,Simon ... confirmed evidences were found after thorough investigation of the outbreak'. ... not been cleared yet but residents who cooked and ate ...
... future for those suffering with the deadly disease of Hepatitis C ... that he would speak with the government for the introduction of ... these diseases while administering blood and blood products. ,This ... , These people suffer from the problem of not ...
... Yale university researchers it was found that forced out of work ... rate of heart attacks //. They analyzed about 4,301 people between ... the study were published in the Occupational and Environmental Medicine journal. ... in about 10 years time period as they were forced out ...
... After the vocal demonstrations in hospitals against reservation policy ... face//. This time it is by the staff ... The bone of contention is the incident wherein some ... administration now is taking steps to check overcrowding of ...
... the Wake Forest University School of Medicine and colleagues ... difficult medical procedures //about the dizzy feel of nausea ... strongly affect how they respond to adversity – both ... Ph.D. ‘Being prepared for difficulty can benefit people greatly.’ ...
Cached Medicine News:Health News:Super-bug MRSA Getting Fitter And Out of Control 2Health News:Precautious Measure Help Tolerate Nausea In Patients 2Health News:Precautious Measure Help Tolerate Nausea In Patients 3
...
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
Lumbar External Drainage System (LED) with Touhy needle is indicated for temporary access to the Lumbar Subarachnoid region as a means of draining cerebral spinal fluid (CSF) in order to reduce incre...
Monitorr ICP external CSF drainage system with self-contained ICP setting....
Medicine Products: